| [1] Doyle LA, Yang WD, Abruzzo LV, Krogmann T, Gao YM, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.[2] Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 2012, 83(8): 1084-1103.[3] Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev, 2009, 61(1): 26-33.[4] Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, Mao Q. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol, 2008, 73(3): 845-854.[5] Evseenko DA, Paxton JW, Keelan JA. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, ster-oids, and growth factors. Drug Metab Dispos, 2007, 35(4): 595-601.[6] Yasuda S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Response of the ABCG2 promoter in T47D cells and BeWo cells to sex hormone treatment. Mol Biol Rep, 2009, 36(7): 1889-1896.[7] Wu XJ, Zhang XF, Zhang H, Su P, Li WW, Li L, Wang Y, Liu WJ, Gao P, Zhou GY. Progesterone receptor down-regulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci, 2012, 103(5): 959-967.[8] Zhang YH, Wang HP, Wei LJ, Li G, Yu J, Gao Y, Gao P, Zhang XF, Wei FL, Yin DL, Zhou GY. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat, 2010, 123(3): 679-689.[9] Hartz AMS, Madole EK, Miller DS, Bauer B. Estrogen receptor β signaling through phosphatase and tensin ho-molog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther, 2010, 334(2): 467-476.[10] Wang HG, Unadkat JD, Mao QC. Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res, 2008, 25(2): 444-452.[11] Wang XD, Wu XG, Wang CK, Zhang WJ, Ouyang YM, Yu YH, He ZM. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-κB pathway in MCF-7 cells. FEBS Lett, 2010, 584(15): 3392-3397.[12] 吴新刚, 彭姝彬, 闾四平, 张年凤, 邹进. p53对乳腺癌耐药蛋白基因的转录调控. 中国生物化学与分子生物学报, 2012, 28(2): 152-157.[13] Zhang WJ, Ding W, Chen Y, Feng ML, Ouyang YM, Yu YH, He ZM. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-κB signaling path-ways in MCF7 breast cancer cells. Acta Biochim Biophys Sin, 2011, 43(8): 647-653.[14] Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem, 2004, 279(23): 24218-24225.[15] Martin CM, Ferdous A, Gallardo T, Humphries C, Sadek H, Caprioli A, Garcia JA, Szweda LI, Garry MG, Garry DJ. Hypoxia-inducible factor-2α transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res, 2008, 102(9): 1075-1081.[16] Reisman SA, Yeager RL, Yamamoto M, Klaassen CD. In-creased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci, 2009, 108(1): 35-47.[17] Singh A, Wu HL, Zhang P, Happel C, Ma JF, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther, 2010, 9(8): 2365-2376.[18] Tan KP, Wang B, Yang MD, Boutros PC, Macaulay J, Xu HB, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, Wu AML, Ross DD, Harper PA, Ito S. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol, 2010, 78(2): 175-185.[19] To KKW, Robey R, Zhan ZR, Bangiolo L, Bates SE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol Cancer Res, 2011, 9(4): 516-527.[20] Tompkins LM, Li HS, Li LH, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang HB. A novel xenobiotic responsive ele-ment regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol, 2010, 80(11): 1754-1761.[21] Szatmari I, Vámosi G, Brazda P, Balint BL, Benko S, Szé-les L, Jeney V, Özvegy-Laczka C, Szántó A, Barta E, Balla J, Sarkadi B, Nagy L. Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem, 2006, 281(33): 23812-23823.[22] Hirai T, Fukui Y, Motojima K. PPARα agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol Pharm Bull, 2007, 30(11): 2185-2190.[23] Meyer SE, Hasenstein JR, Baktula A, Velu CS, Xu Y, Wan HJ, Whitsett JA, Gilks CB, Grimes HL. Krüppel-like fac-tor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. Am J Pathol, 2010, 177(3): 1503-1513.[24] Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Pro-inflammatory cytokines interleukin-1β, interleukin 6, and tumor necrosis factor-α alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem, 2012, 363(1-2): 385-393.[25] Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood- brain barrier. Cell Mol Neurobiol, 2010, 30(1): 63-70.[26] Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements. J Biol Chem, 2010, 85(41): 31100-31106.[27] Ehata S, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, Katsuno Y, Komuro A, Koinuma D, Kano MR, Yashiro M, Hirakawa K, Aburatani H, Fujita N, Miyazono K. Transforming growth factor-β decreases the can-cer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene, 2011, 30(14): 1693-1705.[28] Yin LQ, Castagnino P, Assoian RK. ABCG2 expression and side population abundance regulated by a transform-ing growth factor β-directed epithelial-mesenchymal transition. Cancer Res, 2008, 68(3): 800-807.[29] Imai Y, Ohmori K, Yasuda S, Wada M, Suzuki T, Fukuda K, Ueda Y. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase. Cancer Sci, 2009, 100(6): 1118-1127.[30] Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Onco-gene, 2011, 30(49): 4874-4886.[31] Zheng MH, Zhang ZF, Zhao XC, Ding YQ, Han H. The Notch signaling pathway in retinal dysplasia and retina vascular homeostasis. J Genet Genomics, 2010, 37(9): 573-582.[32] Bhattacharya S, Das A, Mallya K, Ahmad I. Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci, 2007, 120(15): 2652-2662.[33] Hessel S, Lampen A. All-trans retinoic acid enhances the transport of phase II metabolites of benzo[a]pyrene by inducing the Breast Cancer Resistance Protein expression in Caco-2 cells. Toxicol Lett, 2010, 197(2): 151-155.[34] To KKW, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol, 2006, 26(22): 8572-8585.[35] Ji NN, Yuan JH, Liu JJ, Tian SL. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltrans-ferase. Acta Biochim Biophys Sin, 2010, 42(12): 854-862.[36] Bram EE, Stark M, Raz S, Assaraf YG. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia, 2009, 11(12): 1359-1370.[37] To KKW, Polgar O, Huff LM, Morisaki K, Bates SE. His-tone modifications at the ABCG2 promoter fol-lowing treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res, 2008, 6(1): 151-164.[38] Hamada S, Satoh K, Hirota M, Kanno A, Umino J, Ito H, Masamune A, Kikuta K, Kume K, Shimosegawa T. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of trans-porter gene ABCG2. J Cell Physiol, 2012, 227(2): 729-738.[39] Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccarani M, Martinelli G, Perini G. c-MYC oncoprotein dictates transcriptional pro-files of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol Cancer Res, 2011, 9(8): 1054-1066.[40] Petropoulos S, Gibb W, Matthews SG. Breast can-cer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation. Biol Reprod, 2011, 84(4): 783-789. |
